Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL003 in Hypercholesterolemia and Mixed Hyperlipidemia
CTR20230897Phase 2Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL003 in hypercholesterolemia, combined dyslipidaemia, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Mar 2023; status: completed.
02
Drugs
SAL003
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20230897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230897.